Understanding PARK25 (PPP2R4-Related Parkinsonism)
At a Glance
PARK25 is an ultra-rare inherited disorder caused by changes in both copies of the PPP2R4 gene. It combines juvenile-onset parkinsonism—such as slowness and stiffness—with intellectual disability, while its long-term progression remains uncertain.
The path to a diagnosis for a rare condition is often long, exhausting, and filled with uncertainty. If you are reading this, you may have spent years searching for an explanation for a complex set of symptoms that include both movement challenges and learning difficulties. PARK25 (also known as Parkinson disease 25) is an ultra-rare genetic disorder that has only recently been identified in medical literature [1]. Because it is so new and so rare—with only a few families identified worldwide—having a name for it is a significant milestone in your journey [2][3].
Defining PARK25
PARK25 is a specific type of juvenile-onset parkinsonism, a term used when symptoms like stiffness, slowness, or tremors begin before age 21 [4]. (Note that “parkinsonism” describes a movement syndrome and is not synonymous with typical idiopathic Parkinson disease). It is distinct because it almost always appears alongside intellectual disability, which refers to challenges with cognitive functioning and everyday life skills that begin during the developmental period [2].
This condition is associated with biallelic pathogenic variants in a specific gene called PPP2R4 (formerly and also known as PTPA) [2]. Genes are the instruction manuals for the body, and the PPP2R4 gene provides instructions for making a protein that helps regulate other proteins involved in brain health. When this gene has mutations, it can lead to the neurological symptoms seen in PARK25 [5].
The Genetic Cause: The PPP2R4 (PTPA) Gene
In the families identified so far, PARK25 follows an autosomal recessive inheritance pattern [2]. This means that for a person to have the condition, they must inherit two copies of the mutated gene—one from each parent. Parents who carry only one copy of the mutation (called heterozygous carriers) typically do not show any symptoms of the disease [3].
The mutations in the PPP2R4 gene affect the stability of the protein it produces. Research shows that these mutations can lead to:
- Reduced protein levels: The body may not produce enough of the protein [2].
- Impaired activation: The proteins it is supposed to help “turn on” may not function correctly, specifically a complex called PP2A, which is vital for brain cell function [2][3].
Clinical Features: Motor and Neurodevelopmental
PARK25 is characterized by motor and neurodevelopmental features, affecting both the way a person moves and how they learn or process information.
- Motor Symptoms (Parkinsonism): These symptoms often mirror those seen in traditional Parkinson’s disease but appear much earlier in life. They can include bradykinesia (slowness of movement), rigidity (stiffness in the limbs), and sometimes tremors [2]. In some reported cases, these motor symptoms have responded well to a trial of levodopa, a common medication used to manage movement in Parkinson’s, and even to deep-brain stimulation (DBS) [2].
- Cognitive Symptoms (Intellectual Disability): Unlike many other forms of early-onset Parkinson’s, PARK25 is defined by the presence of intellectual disability. This is often noticed early in life, sometimes before the movement symptoms become clear [2]. While one case reported a “minor cognitive decline” later in life, the hallmark of the condition is the foundational intellectual disability present from childhood [3].
Understanding Rarity and What is Uncertain
It is important to emphasize just how rare PARK25 is. At this time, it is considered an emerging cause of early-onset parkinsonism [1]. Medical reports have only documented about three families worldwide as of recently—one from South Africa, one from Libya, and one other consanguineous family [2][3].
Because there are so few cases, the natural history remains uncertain. There is no predictable “standard” progression of the disease. Every person’s experience may be slightly different, and researchers are still learning about the full spectrum of symptoms. This rarity can feel isolating, but it also means that your experience provides vital information to the global medical community’s understanding of this gene.
Looking Forward
While the diagnosis is heavy, it provides a roadmap for care that was likely missing before. Knowing the specific gene involved allows your medical team to look at treatments that have helped the few others with this diagnosis, such as levodopa trials [2]. It also helps in ruling out other conditions that might look similar but require different management [6]. As more is discovered about the PPP2R4 gene and its role in the brain, the hope is that more targeted supportive therapies will become available.
Common questions in this guide
What is PARK25, and how is it different from typical Parkinson disease?
How is PARK25 inherited?
What symptoms can PARK25 cause?
Can levodopa or deep-brain stimulation help with PARK25?
How is PARK25 diagnosed?
What is known about PARK25’s long-term outlook?
How should care be planned when PARK25 includes intellectual disability?
Get notified when new evidence is published on Parkinson disease 25, autosomal recessive early-onset, with impaired intellectual development.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (6)
- 1
The genetics of autosomal recessive early-onset Parkinson's disease.
Cogan G, Lesage S, Brice A
Current opinion in neurobiology 2025; (95()):103141 doi:10.1016/j.conb.2025.103141.
PMID: 41253044 - 2
PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability.
Fevga C, Tesson C, Carreras Mascaro A, et al.
Brain : a journal of neurology 2023; (146(4)):1496-1510 doi:10.1093/brain/awac326.
PMID: 36073231 - 3
Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.
Li C, Lin J, Jiang Q, et al.
Movement disorders : official journal of the Movement Disorder Society 2023; (38(6)):1099-1104 doi:10.1002/mds.29411.
PMID: 37046398 - 4
Juvenile parkinsonism: Differential diagnosis, genetics, and treatment.
Niemann N, Jankovic J
Parkinsonism & related disorders 2019; (67()):74-89 doi:10.1016/j.parkreldis.2019.06.025.
PMID: 31272925 - 5
Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies.
Park HJ, Lee KW, Park ES, et al.
Annals of clinical and translational neurology 2016; (3(10)):769-780 doi:10.1002/acn3.337.
PMID: 27752512 - 6
A Practical Approach to Early-Onset Parkinsonism.
Riboldi GM, Frattini E, Monfrini E, et al.
Journal of Parkinson's disease 2022; (12(1)):1-26 doi:10.3233/JPD-212815.
PMID: 34569973
This page provides general information about PARK25 for educational purposes only and does not constitute medical advice. A neurologist and genetics professional can help interpret PPP2R4 results and tailor treatment and support.